猴痘的眼部表现。
Ocular manifestations of mpox.
机构信息
Francis I. Proctor Foundation, Department of Ophthalmology.
Department of Ophthalmology, University of California, San Francisco, California, USA.
出版信息
Curr Opin Ophthalmol. 2024 Sep 1;35(5):423-429. doi: 10.1097/ICU.0000000000001066. Epub 2024 Jun 6.
PURPOSE OF REVIEW
To highlight the clinical features of mpox with an emphasis on ocular manifestations and to review treatment options for this re-emerging infectious disease.
RECENT FINDINGS
Ocular involvement of mpox varies by clade. The most recent 2022 outbreak appears to be associated with fewer conjunctivitis cases compared to previous outbreaks. However, the ocular findings occurring during this newly emerging clade can be visually threatening and include cases of keratitis, rapidly progressing scleritis, and necrotizing periorbital rashes.
SUMMARY
Ocular mpox is an important clinical feature of systemic mpox virus (MPXV) infection. Heightened clinical suspicion allows for a timely diagnosis and the initiation of antiviral treatment, when appropriate. Randomized clinical trials for mpox systemic and ocular treatment efficacy are lacking. Prior clinical experience with smallpox and in-vitro mpox data support the use of systemic antivirals such as tecovirimat, cidofovir, brincidofovir and topical use of trifluridine in ocular mpox management, though treatment-resistant infection can occur and portend a poor prognosis.
目的综述
强调猴痘的临床特征，重点介绍眼部表现，并回顾这种新发传染病的治疗选择。
最新发现
猴痘的眼部受累因分支而异。与以往疫情相比，最近 2022 年的疫情似乎与较少的结膜炎病例相关。然而，在这种新出现的分支中发生的眼部发现可能具有威胁视力，包括角膜炎、迅速进展的巩膜炎和坏死性眶周皮疹。
总结
眼部猴痘是全身猴痘病毒（MPXV）感染的重要临床特征。提高临床警惕性可以及时诊断并酌情开始抗病毒治疗。缺乏针对猴痘全身和眼部治疗疗效的随机临床试验。以前在天花和体外猴痘数据方面的临床经验支持在眼部猴痘管理中使用全身性抗病毒药物，如特考韦瑞、西多福韦、溴夫定和三氟尿苷，尽管可能会发生耐药感染，并预示预后不良。
Zotero 插件